Cells are grown in 3D culture and topological features obtained by photomicrography are correlated to cell viability and cell cell interactions.

The invention relates to biomarkers and a method of diagnosing or monitoring depression, anxiety disorder or other psychotic disorder.

Cells are grown in 3D culture and topological features obtained by photomicrography are correlated to cell viability and cell interactions.

The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1.sup.+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.

It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.

The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.

Flow cytometry is used for diagnosis of infectious diseases by an analysis of cell mediated immune responses to specific infective agent antigens. Apparatus and methods of advanced flow cytometry are utilized to detect cell mediated immune responses to the presence of specific antigens from infective agents, such as bacteria, protozoa, viruses, helminth, prions. In some embodiments, methods as provided herein can be utilized in vitro to diagnose multiple infections within individuals.

An object of the present invention is to provide a biomarker capable of determining the onset risk or the stage of diabetic nephropathy (early-stage diabetic nephropathy in particular). Diabetic nephropathy is determined by measuring or quantitatively determining a concentration of phenyl sulfate or a salt thereof (a phenyl sulfate) contained in a biological sample, preferably plasma or urine, collected from a test subject to detect a phenyl sulfate. The present invention exhibits excellent effects particularly for stage determination for stage 1 (pre-nephropathy stage) to stage 3 (overt nephropathy stage), or for determination of onset risk of diabetic nephropathy (diabetic nephropathy at pre-nephropathy stage).

A glucose sensor comprises a conducting back electrode. The glucose sensor also comprises a silicon substrate in electrical contact with the conducting back electrode. The glucose sensor also comprises a dielectric layer disposed on the silicon substrate. The glucose sensor also comprises a pH sensing layer disposed on the dielectric layer. The glucose sensor also comprises a chemical layer disposed on the pH sensing layer, wherein the chemical layer is in contact with an aqueous solution. The glucose sensor also comprises a conductive electrode disposed on the dielectric layer, where in the conductive electrode is in contact with the aqueous solution.